New Zealand markets closed
  • NZX 50

    11,180.01
    +89.98 (+0.81%)
     
  • NZD/USD

    0.5737
    +0.0008 (+0.14%)
     
  • NZD/EUR

    0.5753
    +0.0022 (+0.38%)
     
  • ALL ORDS

    7,026.90
    +121.60 (+1.76%)
     
  • ASX 200

    6,812.80
    +113.50 (+1.69%)
     
  • OIL

    86.21
    -0.31 (-0.36%)
     
  • GOLD

    1,727.10
    -3.40 (-0.20%)
     
  • NASDAQ

    11,582.54
    +352.81 (+3.14%)
     
  • FTSE

    7,086.46
    +177.70 (+2.57%)
     
  • Dow Jones

    30,316.32
    +825.43 (+2.80%)
     
  • DAX

    12,670.48
    +461.00 (+3.78%)
     
  • Hang Seng

    18,013.24
    +933.73 (+5.47%)
     
  • NIKKEI 225

    27,106.22
    +114.01 (+0.42%)
     
  • NZD/JPY

    82.6170
    +0.0540 (+0.07%)
     

Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update

·4-min read

Hosting Call on Wednesday, August 24th at 5 pm ET

TORONTO & DALLAS, August 17, 2022--(BUSINESS WIRE)--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company") – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Wednesday, August 24, 2022.

Conference Call/Webcast Information:

Date:

Wednesday, August 24, 2022

Time:

5:00 pm Eastern Time

Dial-In Number:

1-877-704-4453

International Dial-In:

1-201-389-0920

Conference ID:

13732303

Presenters:

Jeremy Sobotta, Chief Executive Officer

Chris Scott, Chief Financial Officer

The call will also be broadcast live online through a listen-only webcast, which will be posted on the Investors section of the Company's website. The webcast will be archived on the Company's investor relations webpage for at least 90 days. A telephonic playback of the conference call will be available for 14 days after the conference call by calling 1-844-512-2921 or 1-412-317-6671 from abroad and referencing conference ID 13732303. The above listed dates and times are subject to change.

About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation, artificial intelligence technology that is currently under clinical development. The company’s ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter’s Management Discussion and Analysis for the year ended December 31, 2021, which is available on Perimeter’s SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005584/en/

Contacts

Jodi Regts
Perimeter Medical Imaging AI, Inc.
Direct: 469-743-1834
Toll-free: 888-988-7465 (PINK)
Investors: investors@perimetermed.com
Media: media@perimetermed.com